Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Dual Combinations for the Treatment of Hypertension

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amlodipine/indapamide/telmisartan-George Medicines (Primary) ; Amlodipine/telmisartan; Indapamide/amlodipine
Indications Hypertension
Focus Registrational; Therapeutic Use
Acronyms GMRx2_ACT
Sponsors George Medicines

31 Aug 2024 According to a George Medicines media release, data from both GMRx2 clinical development program will support additional global regulatory filings.
31 Aug 2024 According to a George Medicines media release, company announced the presentation of results from its two pivotal Phase III trials at a Hot Line session of the European Society of Cardiology (ESC) Annual Meeting in London.
31 Aug 2024 Results presented in the George Medicines Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com